Tharimmune, Inc. stock is down -81.98% since 30 days ago. The next earnings date is Mar 14, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 1 December’s closed higher than November.
Hillstream BioPharma, Inc. develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) The company was incorporated in 2019 and is based in Bridgewater, New Jersey.